The most used ICI-based therapy is anti-PD-1 or anti-PD-L1, which work to block the inhibitory signaling between PD-1, present on the surface of activated T cells, and its ligand PD-L1, expressed on tumor cells [21]. Here, CD274 is linked to neoplasm.